Conceptus Inc

Conceptus — Q3 2010 Earnings Presentation

36 slides from Conceptus's earnings presentation, Oct 28, 2010

  1. Slide 1: Conceptus Inc. Quarterly Results Third Quarter 2010

    Conceptus Inc. Quarterly Results Third Quarter 2010 Exhibit 99.2 © 2010 Conceptus, Inc. All rights reserved. October 28, 2010

  2. Slide 2: Safe Harbor

    Safe Harbor Except for the historical information contained herein, the matters discussed in this presentation include forward-looking statements, the accuracy of which is subject to risks and uncertainties. These forward-looking statements include discussions regarding: projected net sales, net inc

  3. Slide 3: Key Factors

    Key Factors Mark Sieczkarek President and Chief Executive Officer © 2010 Conceptus, Inc. All rights reserved.

  4. Slide 4: Summary of Q3'10

    Summary of Q3’10 Steps we have taken to “control the controllable” in the current environment gained some initial traction Macro economic headwinds continue to cause considerable unpredictability in our business

  5. Slide 5: Key Factors Remain

    Key Factors Remain Macro Factor: 1. Reduced physician office visits due to economy Macro Factor: 2. Currency fluctuations Controllable Factor: 3. Physician metrics growth affected by competitor trialing

  6. Slide 6: Status of Key Factors: Office Visits

    Status of Key Factors: Office Visits Q2’10 Factors Q3’10 Impact Future Expectation 1. Reduced physician office visits Significantly unfavorable Remains unfavorable

  7. Slide 7: Economic Drivers

    Economic Drivers • Continued unemployment at 9.6% • Involuntary part-time workers up to 9.5 million, with few or no benefits • Patients losing insurance coverage (COBRA subsidies ended) or switching to Medicaid • Patients opting for high- deductible health insurance plans and health savings accounts

  8. Slide 8: Reduced Physician Office Visits

    Reduced Physician Office Visits (1) IMS Data provided by Credit Suisse Healthcare Team Domestic general physician office visits remained depressed in Q3’10 (1) . We expect this trend to continue.

  9. Slide 9: Reduced OB/GYN Office Visits

    Reduced OB/GYN Office Visits (1) IMS Data provided by Credit Suisse Healthcare Team Domestic OB/GYN office visits have declined significantly during 2010 (1) . We expect this trend to continue.

  10. Slide 10: Status of Key Factors: Currency

    Status of Key Factors: Currency Q2’10 Factors Q3’10 Impact Future Expectation 1. Reduced physician office visits Significantly unfavorable Remains unfavorable 2. Currency fluctuations Slightly favorable Dollar remains strong against euro

  11. Slide 11: Currency: Dollar vs. Euro

    Currency: Dollar vs. Euro Dollar was weaker to euro than expected in Q3’10 – Modeled exchange rate for H2’10 of $1.20 – Actual exchange rate for Q3’10 was $1.29 – Variance resulted in slight benefit in Q3’10 80% to 90% of international sales are euro denominated

  12. Slide 12: Changes in French Reimbursement

    Changes in French Reimbursement The French government has reduced physician reimbursement for hysteroscopic occlusion procedures for women under the age of 40, effective October 1, 2010 Further cost-cutting measures by the Ministry of Health are expected to affect reimbursements for medical devices

  13. Slide 13: Status of Key Factors: Physician Metrics

    Status of Key Factors: Physician Metrics Q2’10 Factors Q3’10 Impact Future Expectations 1. Reduced physician office visits Significantly unfavorable Remains unfavorable 2. Currency fluctuations Slightly favorable Dollar remains strong against euro 3. Physician metrics: shortfall due to competitor tr

  14. Slide 14: Physician Metrics – Stabilizing in Q3

    Physician Metrics – Stabilizing in Q3 In Q2’10, significant resources were allocated to defend our customer base as competitive trialing ramped, which resulted in a temporary distraction from growing the market through additional physician preceptorships, certifications and transitions to office Sin

  15. Slide 15: Our Priorities: Control the Controllable

    Our Priorities Solution Control the Controllable Solution Solution Re-deploy assets to energize market growth: “back-to-basics” strategy Accelerate growth of physician metrics including new physician adoption of Essure procedure Implement leaner cost structure through discretionary cuts

  16. Slide 16: Back-to-Basics Solution

    Back-to-Basics Solution We are one of the industry’s largest medical device sales teams dedicated to OB/GYN physicians Increased direct sales territories to better align resources Re-deployed existing sales personnel: ~160 sales personnel in the field, with ~120 in direct sales Improved ability to f

  17. Slide 17: Third Quarter 2010 Financials

    Third Quarter 2010 Financials Greg Lichtwardt Executive Vice President, Operations and Chief Financial Officer © 2010 Conceptus, Inc. All rights reserved.

  18. Slide 18: Q3'10 Snapshot

    Q3’10 Snapshot Net Sales ($mm) Gross Margin (%) Diluted Non- GAAP (2) EPS Operating Margin (%) Diluted GAAP EPS Q3’09 Q3’10 Q3’09 Q3’10 Q3’09 Q3’10 Q3’09 Q3’10 Q3’09 Q3’10 $0.29 (1) $34.2 85.3% (1) 80.6% $33.9 23.4% (1) 8.1% $0.20 (1) $0.03 $0.16 Company guidance for Q3’10: Net sales: $33mm to $34mm

  19. Slide 19: Increasing Diversification through International Sales

    Worldwide Sales $28.0 (82%) $27.3 (81%) 20.3 (72%) 7.8 (28%) 19.9 (66%) 10.2 (34%) $6.6 (19%) $6.2 (18%) Increasing Diversification through International Sales The difference between dollar growth and international unit growth is primarily due to average selling price reductions due to customer mix

  20. Slide 20: U.S. Physician Metrics

    U.S. Physician Metrics Q3’10 Q2’10 Q1’09 Q4’09 Q3’09 Current Period Activity: Physicians entering preceptorship Physicians becoming certified Physicians transitioning to office Physician Base: In preceptorship 3,537 3,486 3,434 3,417 3,425 Certified and in hospital 3,267 3,128 2,956 2,793 2,848 Cert

  21. Slide 21: Q3'10 Results

    Q3’10 Q3’09 Y/Y Change Q2’10 Q/Q Change Q3’10 Results Net Sales $33.9 $34.2 (1.1 %) $36.8 (8.0%) Gross Profit Margin 80.6% 85.3% (1) nm 80.2% nm Operating Expenses $24.6 $21.2 15.9% $28.1 (12.7%) Other Income / (Expense) ($1.6) ($1.6) nm ($1.6) nm Tax Provision $0.2 $0.2 nm $0.1 100% NEAT $1.0 $6.2

  22. Slide 22: Q3'10 GAAP vs. Non-GAAP EPS

    Q3’10 GAAP vs. Non-GAAP EPS Non-GAAP EPS $0.16 Amortization of intangibles Stock-based compensation $0.03 $0.06 $0.04 Amortization of non-cash items for convertible notes $0.03 GAAP EPS See GAAP to non-GAAP reconciliation in appendix $976 $810 $1,881 $1,231 $4,898 Actual amount in $ thousands:

  23. Slide 23: Balance Sheet

    Balance Sheet Cash & cash equivalents Investments and put option (1) A/R, inventories & other current assets PP&E Intangible and other assets Goodwill Total assets ASSETS 19.3 64.0 28.2 10.4 26.2 16.4 164.5 61.7 43.5 25.7 9.8 29.1 17.3 187.1 9/30/10 A/P & other accrued ST liabilities Line of credit

  24. Slide 24: Guidance

    Guidance Q4’09A FY’09A Q4’10E FY’10E Net Sales $39 mm to $41 mm $143 mm to $145 mm $37.0 $131.4mm Gross Profit Margin 82.2% 81.1% 82.2% 81.7% Operating Expenses $22.0mm $102.5mm $22.2mm $92.7mm Net Income $8.3 mm to $9.9 mm $6.6 mm to $8.3 mm $6.6mm $7.9mm GAAP EPS (diluted) $0.26 to $0.31 $0.21 to

  25. Slide 25: Competitive Environment & Road to Standard of Care

    Competitive Environment & Road to Standard of Care Mark Sieczkarek President and Chief Executive Officer © 2010 Conceptus, Inc. All rights reserved.

  26. Slide 26: Essure: Beats PBC Competition

    Essure: Beats PBC Competition Permanent birth control failures per 1,000 women at 3 years: Essure: 1.6 (1) Tubal ligation: 9.9 (2) Vasectomy: 11.3 (3) Competitor’s procedure: 16 (4) ………………... .……… .......... ... (1) Essure Effectiveness Report (data 12/16/04) page 14 (2) Peterson, H.B., et al. The r

  27. Slide 27: Essure: Long Term Efficacy Will Win

    Essure: Long Term Efficacy Will Win Essure Competitor’s product Clinical 0 pregnancies reported 12 pregnancies reported 99.84% effective at 3 years label claim or 1 in 625 98.4% effective at 3 years label claim or 1 in 62 Commercial pregnancies reported against 465,000 procedures or 1 in 700 ? Data

  28. Slide 28: Essure: Latest Research

    Essure: Latest Research “Permanent birth control with Essure device has demonstrated to be a safe method, with low rate of complications, which its security persist(s) after 8 years follow up. That means that Essure method should be the reference method in what is to do with definitive contraception

  29. Slide 29: Status of Competitive Trialing

    Status of Competitive Trialing 7,000 total Essure accounts – 1,500 to 2,000 anticipated to trial – 800 to 900 have trialed to date Expect trialing to last 9 to 15 months if physician utilization stays steady at 1 to 2 hysteroscopic sterilization procedures per month Many mature trialing accounts hav

  30. Slide 30: Multi-Billion Dollar Market

    Multi-Billion Dollar Market Our future market: Tubal ligations (2) : 643,000 Our current addressable market “Sweet Spot” Essure: 30,000 Permanent birth control procedures each year 673,000 In millions Base of 38 million women (1) 2006-08 CDC report, Data from the National Survey of Family Growth, pu

  31. Slide 31: Road to Standard of Care

    Road to Standard of Care Future milestones: Conceptus founded EU approves Essure FDA approves Essure 6,000 hysteroscopically trained physicians Minimal patient awareness 465,000 women rely on Essure 15,000 hysteroscopically trained physicians 30% patient awareness Hysteroscopic tubal occlusion 14% o

  32. Slide 32: Appendix

    Appendix © 2010 Conceptus, Inc. All rights reserved.

  33. Slide 33: Use of Non-GAAP Financial Measures

    Use of Non-GAAP Financial Measures The Company has supplemented its GAAP results of operations with a non-GAAP measure of net income (loss) and has supplemented its GAAP guidance with a non- GAAP measure of non-GAAP earnings per share. In each case, the non-GAAP measure excludes stock-based compensa

  34. Slide 34: GAAP to Non-GAAP Reconciliation

    GAAP to Non-GAAP Reconciliation Net income (loss), as reported $ 6,232 $ (1,665) $ 1,341 $ Adjustments to net income (loss): Amortization of intangibles (a) 2,437 Stock-based compensation (b) 1,881 1,626 5,412 4,556 Amortization of non-cash interest expense (c) 1,115 1,054 3,298 3,118 Amortization o

  35. Slide 35: GAAP to Non-GAAP Reconciliation

    GAAP to Non-GAAP Reconciliation From To From To GAAP Guidance 0.26 $ 0.31 $ 0.21 $ 0.26 $ Estimated Non-GAAP Guidance Amortization of intangibles (a) 0.03 $ 0.03 $ 0.10 $ 0.10 $ Stock-based compensation (b) 0.06 $ 0.06 $ 0.24 $ 0.24 $ Amortization of non-cash items for convertible note (c) 0.04 $ 0.

  36. Slide 36: Thank You

    Thank You © 2010 Conceptus, Inc. All rights reserved. CC-2551 27OCT10F

Conceptus — Q3 2010 Earnings Presentation on 6ix